Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 257

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Australian and New Zealand Clinical Practice Guidelines for the Treatment of Depression

Royal Australian And New Zealand College Of Psychiatrists Clinical Practice Guidelines Team For Depression·2004·Australian & New Zealand Journal of Psychiatry
DOI 10.1080/j.1440-1614.2004.01377.x
Open this paper in CoChat — free account

Abstract

Background: The Royal Australian and New Zealand College of Psychiatrists (RANZCP) is co-ordinating the development of clinical practice guidelines (CPGs) in psychiatry, funded under the National Mental Health Strategy (Australia) and the New Zealand Ministry of Health. Method: The CPG team reviewed the treatment outcome literature, consulted with practitioners and patients and conducted meta-analyses of outcome research. Treatment recommendations: Establish an effective therapeutic relationship; provide the patient with information about the condition, the rationale for treatment, the likelihood of a positive response and the expected timeframe; consider the patient's strengths, life stresses and supports. Treatment choice depends on the clinician's skills and the patient's circumstances and preferences, and should be guided but not determined by these guidelines. In moderately severe depression, all recognized antidepressants, cognitive behavioural therapy (CBT) and interpersonal psychotherapy (IPT) are equally effective; clinicians should consider treatment burdens as well as benefits, including side-effects and toxicity. In severe depression, antidepressant treatment should precede psychological therapy. For depression with psychosis, electroconvulsive therapy (ECT) or a tricyclic combined with an antipsychotic are equally helpful. Treatments for other subtypes are discussed. Caution is necessary in people on other medication or with medical conditions. If response to an adequate trial of a first-line treatment is poor, another evidence-based treatment should be used. Second opinions are useful. Depression has a high rate of recurrence and efforts to reduce this are crucial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/j.1440-1614.2004.01377.x

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 231

  1. 1. Ellis P M, Smith D AR. Treating depression: the beyondblue guidelines for treating depression in primary care. ‘Not so much what you do but that you keep doing it’. Medical Journal of Australia 2002; 176(Suppl.)S77–S83.
  2. 2. National Health Committee. Guidelines for the treatment and management of depression by primary healthcare professionals. Ministry of Health, Wellington 1996.
  3. 3. Health and Medical Research Council. Getting up from feeling down: young people and depression. National Health and Medical Research Council, Canberra 1997.
  4. 4. Andrews G. Brief report provided to the New Zealand Treasury on the prevalence and disability of DSM-IV disorders from the 1997 Australian National Survey of Mental Health and Well-being. New Zealand Treasury, Wellington 2000.
  5. 5. McLennan W. Mental health and wellbeing: profile of adults, Australia 1997. Australian Bureau of Statistics, Canberra 1998.
  6. 10.1001/archpsyc.1995.03950130011002 · DOI · Paper page
  7. 8. Murray C JL, Lopez A D. The global burden of disease: a comprehensive assessment of mortality and disability from disease, injuries and risk factors in 1990 and projected to 2020, Murray C JL, Lopez A D. Harvard University Press, Cambridge, MA 1996.
  8. 10.3109/00048678409158781 · DOI
  9. 10.1001/archinte.1990.00390170008002 · doi:10.1001/archinte.1990.00390170008002
  10. 10.1097/00004583-199201000-00009 · DOI · Paper page
  11. 10.3109/00048679409075849 · DOI · Paper page
  12. 13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 4th edn. American Psychiatric Press, Washington, DC 1994.
  13. 14. Mulrow C D, Williams J W, Trivedi M, Chiquette E, Aguilar C, Cornell J E. Treatment of depression: Newer pharmacotherapies: AHCPR. Agency for Healthcare Policy and Research, Rockville, MD 1999.
  14. 15. Keller M B, Lavori P W. Double depressive disorder, major depressive disorder and dysthymic disorder. Distinct entities or different phases of a single disorder?. Psychopharmacology Bulletin 1984; 20: 399–402.
  15. 10.1001/archpsyc.1992.01820100053010 · DOI · Paper page
  16. 10.1192/bjp.153.6.741 · DOI · Paper page
  17. 10.1001/archpsyc.55.8.694 · DOI · Paper page
  18. 10.2165/00023210-199504040-00004 · DOI
  19. 10.1017/S0033291701004743 · DOI
  20. 10.1192/bjp.172.1.35 · DOI · Paper page
  21. 10.1176/ajp.145.7.849 · DOI
  22. 23. Hyman S, Arana G W. Suicide and affective disorder. Sucide: understanding and responding, Jacobs D BH. International University Press, Madison 1990; 171–181.
  23. 10.1111/j.1749-6632.1986.tb27909.x · DOI
  24. 10.1111/j.1600-0447.1989.tb01318.x · DOI · Paper page
  25. 10.1016/0165-0327(96)00050-X · DOI
  26. 10.1192/bjp.174.3.259 · DOI
  27. 10.1176/ajp.156.2.190 · DOI · Paper page
  28. 10.1192/bjp.175.2.168 · DOI · Paper page
  29. 10.1176/ajp.152.7.1002 · DOI
  30. 10.1136/bmj.317.7151.115 · DOI · Paper page
  31. 33. Kendler K S, Kessler R C, Neale M C, Heath A C, Eaves L J. The prediction of Major Depression in women: Towards an integrated aetiological model. American Journal of Psychiatry 1993; 150: 863–870.
  32. 10.1192/bjp.163.6.733 · DOI
  33. 10.1192/bjp.163.6.739 · DOI
  34. 10.1192/bjp.165.4.447 · DOI · Paper page
  35. 10.1192/bjp.165.4.457 · DOI
  36. 38. Thase M E. Treatment of severe depression. Journal of Clinical Psychiatry 2000; 61(Suppl.1)17–25.
  37. 10.1017/S0033291700027860 · DOI · Paper page
  38. 10.1017/S0033291700001975 · DOI · Paper page
  39. 10.1016/0165-0327(90)90063-E · DOI
  40. 10.1001/jama.1989.03420150079041 · DOI · Paper page
  41. 10.1177/106286060101600205 · doi:10.1177/106286060101600205
  42. 45. Zorrilla E P, McKay J R, Luborsky L, Schmidt K. Relation of stressors and depressive symptoms to clinical progression of viral illness [Comment]. American Journal of Psychiatry 1996; 154: 718.
  43. 10.1258/0956462971920000 · doi:10.1258/0956462971920000
  44. 10.1016/0022-3999(95)00615-X · DOI
  45. 10.1097/00002826-200201000-00004 · DOI
  46. 49. Ruoff G E. Depression in the patient with chronic pain. Journal of Family Practice 1996; 43(Suppl.)S25–S33.
  47. 10.1136/jnnp.23.1.56 · DOI · Paper page
  48. 51. Mietinnen O, Nurminnen M. Comparative analysis of two rates. Statistics in Medicine 1985; 17: 873–890.
  49. 10.1177/014662167700100306 · DOI · Paper page
  50. 10.1016/S0735-6757(03)00039-1 · DOI
  51. 10.1016/S0165-0327(00)00232-9 · DOI
  52. 10.1097/00004850-199300730-00006 · DOI
  53. 10.1001/archpsyc.59.3.233 · DOI
  54. 10.1192/bjp.174.3.219 · DOI
  55. 10.1192/bjp.174.3.225 · DOI
  56. 10.1136/bmj.310.6977.441 · DOI · Paper page
  57. 10.1136/bmj.320.7226.26 · DOI · Paper page
  58. 10.1093/bmb/57.1.115 · DOI
  59. 10.3310/hta4190 · DOI · Paper page
  60. 10.1034/j.1600-0447.2000.101005343.x · DOI
  61. 10.1192/bjp.179.2.95 · DOI
  62. 10.1001/archpsyc.1984.01790120037006 · DOI · Paper page
  63. 10.4088/JCP.v63n0510 · DOI
  64. 70. American Psychiatric Association. The practice of electroconvulsive therapy: Recommendations for treatment, training and privileging. American Psychiatric Press, Washington, DC 1990.
  65. 71. Freeman C P. The ECT handbook. Gaskell, London 1995, (Council report CR39).
  66. 10.1016/S0165-0327(99)00096-8 · DOI
  67. 10.1192/bjp.146.6.576 · DOI
  68. 10.1016/S0193-953X(05)70353-1 · DOI
  69. 10.1001/archpsyc.59.8.723 · DOI
  70. 10.3109/10673229809003578 · DOI · Paper page
  71. 10.1001/archpsyc.1988.01800260037004 · DOI · Paper page
  72. 10.1001/archpsyc.56.5.431 · DOI · Paper page
  73. 10.1097/00004714-199812000-00002 · DOI
  74. 10.1176/ajp.145.3.306 · DOI · Paper page
  75. 10.1001/archpsyc.1990.01810220051006 · DOI
  76. 10.1016/0165-1781(80)90019-0 · doi:10.1016/0165-1781(80)90019-0
  77. 10.1176/ajp.138.3.328 · DOI · Paper page
  78. 10.1097/00005053-198210000-00008 · DOI
  79. 10.1097/00005053-197912000-00002 · DOI
  80. 87. Spiker D G, Hanin I, Perel J M, Cofsky J E, Rossi A J, Sorisio D. Pharmacological treatment of delusional depressives. Psychopharmacology Bulletin 1982; 18: 184–186.
  81. 10.1176/ajp.142.4.430 · DOI · Paper page
  82. 89. Glassman A H, Kantor S J, Shostak M. Depression, delusions and drug response. American Journal of Psychiatry 1975; 132: 462–463.
  83. 10.1192/bjp.131.5.493 · doi:10.1192/bjp.131.5.493
  84. 10.1176/ajp.1979.136.4b.559 · DOI · Paper page
  85. 10.1016/S0165-0327(99)00079-8 · DOI · Paper page
  86. 10.1001/archpsyc.58.4.381 · DOI · Paper page
  87. 10.1001/archpsyc.58.3.241 · DOI · Paper page
  88. 95. Medicines in Pregnancy Working Party of the Australian Drug Evaluation Committee. Prescribing medicines in pregnancy. An Australian categorization of risk of drug use in pregnancy 4th edn. Therapeutic Goods Administration, Canberra 1999.
  89. 10.2165/00128072-200002030-00003 · DOI
  90. 97. Anonymous. Drugs and breast feeding. Prescribe International 2002; 11: 17.
  91. 10.1016/S0165-0327(00)00332-3 · DOI
  92. 99. Ballenger J C, Davidson J R, Lecrubier Y, . Consensus statement on depression, anxiety, and oncology. Journal of Clinical Psychiatry 2001; 62(Suppl.8)64–67.
  93. 100. Gill D, Hatcher S. Database of systematic reviews (4). Cochrane Database of Systematic Reviews CD001312 2000.
  94. 10.1067/mhj.2000.109977 · DOI
  95. 10.1097/00126334-200212010-00006 · doi:10.1097/00126334-200212010-00006
  96. 10.3109/10673229809000307 · DOI
  97. 10.1001/archpsyc.58.3.221 · DOI · Paper page
  98. 106. Glassman A H. Cardiovascular effects of antidepressant drugs: updated. Journal of Clinical Psychiatry 1998; 59(Suppl.15)13–18.
  99. 10.1016/j.amjcard.2003.08.006 · DOI
  100. 10.1093/hrp/7.2.85 · DOI
  101. 109. Rosenstein D L, Nelson J C, Jacobs S C. Seizures associated with antidepressants: a review. Journal of Clinical Psychiatry 1993; 54: 289–299.
  102. 10.1016/S0033-3182(87)72555-9 · doi:10.1016/s0033-3182(87)72555-9
  103. 10.1034/j.1600-0447.2000.102004250.x · doi:10.1034/j.1600-0447.2000.102004250.x
  104. 10.1111/j.1600-0447.1997.tb10145.x · doi:10.1111/j.1600-0447.1997.tb10145.x
  105. 10.1046/j.1365-2125.2002.01572_1.x · doi:10.1046/j.1365-2125.2002.01572_1.x
  106. 114. Martin J L, Barband M J, Schlaepfer T E, . Transcranial magnetic stimulation for treating depression. Cochrane Database of Systematic Reviews CD003493 2002; 2.
  107. 10.1034/j.1600-0447.2000.102001003.x · DOI
  108. 116. Shaw K, Turner J, Del Mar C. Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database of Systematic Reviews 2003; 3.
  109. 117. Jorm A F, Christensen H, Griffiths K M, Rodgers B. Effectiveness of complementary and self-help treatments for depression. Medical Journal of Ausstralia 2002; 176(Suppl.)S84–S96.
  110. 118. Delgado P L. Approaches to the enhancement of patient adherence to antidepressant medication treatment. Journal of Clinical Psychiatry 2000; 61(Suppl.2)6–9.
  111. 10.1176/appi.ajp.157.8.1195 · DOI · Paper page
  112. 10.1176/appi.ajp.159.9.1470 · DOI · Paper page
  113. 121. Stark P, Hardison C D. A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder. Journal of Clinical Psychiatry 1985; 46: 53–58.
  114. 122. Cohn J B, Wilcox C S. Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: a double-blind study. Journal of Clinical Psychiatry 1986; 47: 409–412.
  115. 10.1176/ajp.143.1.88 · doi:10.1176/ajp.143.1.88
  116. 10.1111/j.1600-0447.1989.tb07190.x · DOI
  117. 126. Lydiard R B, Laird L K, Morton W AJr, Fluvoxamine, imipramine, and placebo in the treatment of depressed outpatients: effects on depression. Psychopharmacology Bulletin 1989; 25: 68–70.
  118. 127. Reimherr F W, Chouinard G, Cohn C K, . Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. Journal of Clinical Psychiatry 1990; 51(Suppl. B)18–27.
  119. 128. Fontaine R, Ontiveros A, Elie R, . A double-blind comparison of nefazodone, imipramine, and placebo in major depression. Journal of Clinical Psychiatry 1994; 55: 234–241.
  120. 129. Schweizer E, Feighner J, Mandos L A, . Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. Journal of Clinical Psychiatry 1994; 55: 104–108.
  121. 10.1192/bjp.164.6.802 · DOI
  122. 10.1097/00004850-199400920-00005 · DOI
  123. 132. Bremner J D. A double-blind comparison of Org 3770, amitriptyline and placebo in major depression. Journal of Clinical Psychiatry 1995; 56: 519–525.
  124. 133. Fabre L, Birkhimer L J, Zaborny B A, Wong L F, Kapik B M. Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients. International Clinical Psychopharmacology 1996; 11: 119–127.
  125. 134. Cohn C K, Robinson D S, Roberts D L, . Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression. Journal of Clinical Psychiatry 1996; 57(Suppl.2)15–18.
  126. 10.1111/j.1600-0447.1997.tb10136.x · DOI
  127. 10.1136/bmj.319.7224.1534 · DOI · Paper page
  128. 10.1111/j.1600-0447.1988.tb06353.x · DOI
  129. 10.1111/j.1600-0447.1989.tb07188.x · DOI
  130. 139. Laughren T P. The review of clinical safety data in a new drug application. Psychopharmacology Bulletin 1989; 25: 5–8.
  131. 140. Dunlop S R, Dornseif B E, Wernicke J F, . Pattern analysis shows beneficial effect of fluoxetine treatment in mild depression. Psychopharmacology Bulletin 1990; 26: 173–180.
  132. 141. Kiev A. A double-blind, placebo-controlled study of paroxetine in depressed outpatients. Journal of Clinical Psychiatry 1992; 53(Suppl.)27–29.
  133. 142. Smith W T, Glaudin V. A placebo-controlled trial of paroxetine in the treatment of major depression. Journal of Clinical Psychiatry 1992; 53: 36–39.
  134. 143. Claghorn J L. The safety and efficacy of paroxetine compared with placebo in a double-blind trial of depressed outpatients. Journal of Clinical Psychiatry 1992; 53(Suppl.)33–35.
  135. 10.1097/00004850-199300840-00007 · DOI
  136. 145. Fabre L BL, Birkhimer L J, Zaborny B A, Wong L F, Kapik B M. Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients. International Clinical Psychopharmacology 1996; 11: 119–127.
  137. 146. Massana J. Reboxetine versus fluoxetine. an overview of efficacy and tolerability. Journal of Clinical Psychiatry 1998; 59(Suppl.)8–10.
  138. 10.1016/S0924-9338(97)86377-8 · DOI
  139. 148. Schweizer E, Feighner J, Mandos L A, Rickels K. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. Journal of Clinical Psychiatry 1994; 55: 104–108.
  140. 10.4088/JCP.v58n0904 · DOI
  141. 10.4088/JCP.v59n0305 · DOI
  142. 10.1097/00004714-199802000-00004 · DOI
  143. 153. Smith W T, Glaudin V, Panagides J, . Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder. Psychopharmacology Bulletin 1990; 26: 191–196.
  144. 10.4088/JCP.v59n0508 · DOI · Paper page
  145. 10.1007/BF01173752 · DOI
  146. 156. Lydiard R B, Laird L K, Morton W AJr. Fluvoxamine, imipramine, and placebo in the treatment of depressed outpatients: effects on depression. Psychopharmacology Bulletin 1989; 25: 68–70.
  147. 157. Tignol J, Stoker M J, Dunbar G C. Paroxetine in the treatment of melancholia and severe depression. International Clinical Psychopharmacology 1992; 7: 91–94.
  148. 10.1176/ajp.151.12.1735 · DOI · Paper page
  149. 10.1097/00004850-200015050-00003 · DOI · Paper page
  150. 10.1192/bjp.160.4.519 · DOI
  151. 10.1097/00004850-199409000-00001 · DOI · Paper page
  152. 10.1097/00004850-200015010-00004 · DOI
  153. 164. Feiger A, Kiev A, Shrivastava R K, Wisselink P G, Wilcox C S. Nefazadone versus sertraline in outpatients with major depression: Focus on efficacy, tolerability and effects on sexual function and satisfaction. Journal of Clinical Psychiatry 1996; 57(Suppl.2)53–62.
  154. 165. Feighner J P. A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder. Journal of Clinical Psychiatry 1985; 46: 369–372.
  155. 166. Fawcett J, Zajecka J M, Kravitz H M, . Fluoxetine versus amitriptyline in adult outpatients with major depression. Current Therapeutic Research 1989; 45: 821–831.
  156. 10.1111/j.1600-0447.1989.tb07192.x · DOI
  157. 168. Levine S, Deo R, Mahadevan K. A comparative trial of a new antidepressant, fluoxetine. International Clinical Psychopharmacology 1989; 4(Suppl.1)41–45.
  158. 169. Perry P J, Garvey M J, Kelly M W, Cook B L, Dunner F J, Winokur G. A comparative trial of fluoxetine versus trazodone in outpatients with major depression. Journal of Clinical Psychiatry 1989; 50: 290–294.
  159. 10.1016/0165-0327(90)90081-I · DOI · Paper page
  160. 171. Dowling B, Webb M GT, Halpin C M, . Fluoxetine: a comparative study with dothiepin. Irish Journal of Psychiatry 1990; Spring: 3–7.
  161. 10.1097/00004850-199100620-00007 · DOI
  162. 10.1097/00004850-199206004-00009 · DOI
  163. 10.1097/00004850-199206004-00008 · DOI
  164. 10.1111/j.1600-0447.1992.tb03294.x · DOI
  165. 10.1097/00004714-199310000-00002 · DOI
  166. 10.1097/00004850-199300830-00002 · DOI
  167. 10.1055/s-2007-1014346 · DOI
  168. 10.1097/00004850-199403001-00007 · DOI · Paper page
  169. 10.1097/00004850-199400920-00005 · DOI
  170. 10.1097/00004714-199408000-00003 · DOI
  171. 10.4088/JCP.v58n0305 · DOI
  172. 10.1002/(SICI)1099-1077(199705/06)12:3<203::AID-HUP849>3.0.CO;2-V · doi:10.1002/(sici)1099-1077(199705/06)12:3<203::aid-hup849>3.0.co;2-v
  173. 10.1016/S0033-3182(97)71461-0 · DOI · Paper page
  174. 10.1016/S0924-977X(97)00418-5 · DOI
  175. 10.4088/JCP.v59n1107 · DOI · Paper page
  176. 10.1176/ajp.156.7.1024 · DOI
  177. 10.1001/archpsyc.57.1.76 · DOI
  178. 10.1177/026988110001400108 · DOI
  179. 192. Tylee A, Beaumont G, Bowden M W, . A double-blind, randomised, 12-week comparison study of the safety and the efficacy of venlafaxine and fluoxetine in moderate to severe major depression in general practice. Primary Care Psychiatry 1997; 3: 51–58.
  180. 10.4088/JCP.v59n0703 · DOI
  181. 10.4088/JCP.v61n0204 · DOI
  182. 196. Zivlov M, de Jongh G D. A 6-week randomised, double-blind multicentre trial in hospitalised depressed patients. Human Psychopharmacology 1995; 10: 173–180.
  183. 10.1002/hup.470100807 · DOI
  184. 10.1002/hup.470100403 · DOI
  185. 10.1097/00002826-199417001-00007 · DOI
  186. 10.1097/00004850-199705000-00007 · DOI
  187. 202. Lapierre Y D, Joffe R, McKenna K, . Moclobemide versus fluoxetine in the treatment of major depressive disorders in adults. Journal of Psychiaty and Neuroscience 1997; 22: 118–126.
  188. 10.1056/NEJM200005183422001 · DOI · Paper page
  189. 10.1192/bjp.166.1.80 · DOI · Paper page
  190. 10.1176/ajp.151.9.1372 · DOI · Paper page
  191. 10.1097/00004714-199608000-00006 · DOI · Paper page
  192. 10.1176/ajp.126.4.457 · DOI · Paper page
  193. 10.1176/ajp.139.1.34 · DOI · Paper page
  194. 209. Thase M E, Kupfer D J, Frank E, Jarrett D B. Treatment of imipramine-resistant recurrent depression. II. An open clinical trial of lithium augmentation. Journal of Clinical Psychiatry 1989; 50: 385–388.
  195. 210. Steiner M, Radwan M, Elizur A, Blum I, Atsmon A, Davidson S. Failure of 1-triiodothyronine to potentiate tricylic antidepressant response. Current Therapeutic Research 1978; 23: 655–659.
  196. 10.1001/archpsyc.1993.01820170065008 · DOI · Paper page
  197. 10.1001/archpsyc.56.4.375 · DOI
  198. 10.1001/archpsyc.1994.03950030084009 · DOI · Paper page
  199. 10.2190/6T1E-A6E1-V2J6-JL99 · DOI
  200. 10.1176/ajp.155.10.1346 · DOI

200 of 231 shown

Cited by

See all 257

Metadata

Authors
Royal Australian And New Zealand College Of Psychiatrists Clinical Practice Guidelines Team For Depression
Venue
Australian & New Zealand Journal of Psychiatry
Publisher
SAGE Publications
Published
2004-06
Volume
38
Issue
6
Pages
389-407
ISSN
  • 0004-8674 (ISSN-L)
  • 1440-1614
DOI
10.1080/j.1440-1614.2004.01377.x
OpenAlex
W1700015166
Cited by
257
References
16
FWCI
8.60
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Australian and New Zealand Clinical Practice Guidelines for the Treatment of Depression. https://app.cochat.ai/papers/10.1080/j.1440-1614.2004.01377.x
The paper
Royal Australian And New Zealand College Of Psychiatrists Clinical Practice Guidelines Team For Depression. (2004). Australian and New Zealand Clinical Practice Guidelines for the Treatment of Depression. Australian & New Zealand Journal of Psychiatry. https://doi.org/10.1080/j.1440-1614.2004.01377.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.